Mga Batayang Estadistika
| LEI | 549300JOU6AK8387EW77 |
| CIK | 1453593 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Xtant Medical Holdings, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34951 XTANT MEDI |
|
| August 12, 2025 |
Exhibit 99.1 Xtant Medical Reports Second Quarter 2025 Financial Results Total Revenue of $35.4 Million Increased 18% Year-over-Year Delivers Positive Net Income, Adjusted EBITDA and Operating Cash Flow Raises FY25 Revenue Guidance to $131-$135 Million, Representing Growth of 11%-15% over FY24 BELGRADE, Mont., August 12, 2025 — Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical t |
|
| August 12, 2025 |
Investor Presentation of Xtant Medical Holdings, Inc. (August 2025) (furnished herewith) Exhibit 99.2 |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2025 XTANT MEDICAL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34951 20-5313323 (State or other jurisdiction of incorporation) (Commi |
|
| August 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2025 XTANT MEDICAL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34951 20-5313323 (State or other jurisdiction of incorporation) (Commis |
|
| August 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2025 XTANT MEDICAL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34951 20-5313323 (State or other jurisdiction of incorporation) (Commis |
|
| July 8, 2025 |
Exhibit 10.2 Execution Version Limited consent AND AMENDMENT NO. 3 to AMENDED AND RESTATED CREDIT, SECURITY AND GUARANTY AGREEMENT (REVOLVING LOAN) AND AMENDMENT NO. 1 TO PLEDGE AGREEMENT This LIMITED CONSENT AND AMENDMENT NO. 3 TO AMENDED AND RESTATED CREDIT, SECURITY AND GUARANTY AGREEMENT (REVOLVING LOAN) AND AMENDMENT NO. 1 TO PLEDGE AGREEMENT (this “Agreement”) is made as of July 7, 2025, by |
|
| July 8, 2025 |
Exhibit 2.1 ASSET PURCHASE AGREEMENT This Asset Purchase Agreement (this “Agreement”) dated July 7, 2025, by and between XTANT MEDICAL HOLDINGS, INC., a Delaware corporation (the “Xtant”), SURGALIGN SPV, INC., a Delaware corporation, (“Surgalign” and together with Xtant, the “Company Group”), and COMPANION SPINE, LLC, a Delaware limited liability company, or its Affiliate designee (“Buyer”). The C |
|
| July 8, 2025 |
Exhibit 10.1 Execution Version Limited consent AND AMENDMENT NO. 3 to AMENDED AND RESTATED CREDIT, SECURITY AND GUARANTY AGREEMENT (TERM LOAN) AND AMENDMENT NO. 1 TO PLEDGE AGREEMENT This LIMITED CONSENT AND AMENDMENT NO. 3 TO AMENDED AND RESTATED CREDIT, SECURITY AND GUARANTY AGREEMENT (TERM LOAN) AND AMENDMENT NO. 1 TO PLEDGE AGREEMENT (this “Agreement”) is made as of July 7, 2025, by and among |
|
| July 8, 2025 |
Exhibit 99.1 Xtant Medical Announces Definitive Agreements for the Sale of its Coflex® and CoFix® Spinal Implants and All OUS Businesses to Companion Spine Transaction expected to facilitate enhanced focus on Xtant’s core businesses Total consideration of approximately $19.2 million allows Xtant to reduce outstanding debt and improve liquidity BELGRADE, Mont., July 7, 2025 - Xtant Medical Holdings |
|
| July 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2025 XTANT MEDICAL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34951 20-5313323 (State or other jurisdiction of incorporation) (Commissi |
|
| July 8, 2025 |
Exhibit 2.2 EQUITY PURCHASE AGREEMENT This Equity Purchase Agreement (this “Agreement”) dated July 7, 2025, by and between XTANT MEDICAL HOLDINGS, INC., a Delaware corporation (the “Seller”), PARADIGM SPINE GMBH, a German Gesellschaft mit beschränkter Haftung (the “Company”) and COMPANION SPINE, LLC, a Delaware limited liability company (“Buyer”). The Seller, the Company and Buyer are referred to |
|
| May 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Xtant Medical Holdings, Inc. (Exact name of the registrant as specified in its charter) Delaware 001-34951 20-5313323 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) 664 Cruiser Lane Belgrade, MT 59714 (Address of |
|
| May 20, 2025 |
73,114,592 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration Statement No.: 333-287192 FINAL PROSPECTUS 73,114,592 Shares of Common Stock This prospectus relates to the resale, from time to time, of up to an aggregate of 73,114,592 shares of common stock, par value $0.000001 per share, of Xtant Medical Holdings, Inc. by the selling stockholders named in this prospectus, including their respective donees, pledgee |
|
| May 15, 2025 |
664 Cruiser Lane Belgrade, Montana 59714 (406) 388-0480 664 Cruiser Lane Belgrade, Montana 59714 (406) 388-0480 May 15, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, DC 20549 Attention: Jason Drory Re: Xtant Medical Holdings, Inc. |
|
| May 12, 2025 |
As filed with the Securities and Exchange Commission on May 12, 2025 As filed with the Securities and Exchange Commission on May 12, 2025 Registration No. |
|
| May 12, 2025 |
As filed with the Securities and Exchange Commission on May 12, 2025 As filed with the Securities and Exchange Commission on May 12, 2025 Registration No. |
|
| May 12, 2025 |
As filed with the Securities and Exchange Commission on May 12, 2025 As filed with the Securities and Exchange Commission on May 12, 2025 Registration No. |
|
| May 12, 2025 |
As filed with the Securities and Exchange Commission on May 12, 2025 As filed with the Securities and Exchange Commission on May 12, 2025 Registration No. |
|
| May 12, 2025 |
As filed with the U.S. Securities and Exchange Commission on May 12, 2025 As filed with the U.S. Securities and Exchange Commission on May 12, 2025 Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Xtant Medical holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 3841 20-5313323 (State or other jurisdiction of incorporation or |
|
| May 12, 2025 |
As filed with the Securities and Exchange Commission on May 12, 2025 As filed with the Securities and Exchange Commission on May 12, 2025 Registration No. |
|
| May 12, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Xtant Medical Holdings, Inc. |
|
| May 12, 2025 |
As filed with the Securities and Exchange Commission on May 12, 2025 As filed with the Securities and Exchange Commission on May 12, 2025 Registration No. |
|
| May 12, 2025 |
Exhibit 99.1 Xtant Medical Reports First Quarter 2025 Financial Results Revenue Increases 18% Year-over-Year Delivers Positive Net Income and $1.3 Million in Operating Cash Flow Increases 2025 Revenue Guidance to $127 Million to $131 Million BELGRADE, Mont., May 12, 2025 — Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the |
|
| May 12, 2025 |
As filed with the Securities and Exchange Commission on May 12, 2025 As filed with the Securities and Exchange Commission on May 12, 2025 Registration No. |
|
| May 12, 2025 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2025 XTANT MEDICAL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34951 20-5313323 (State or other jurisdiction of incorporation) (Commissi |
|
| May 12, 2025 |
As filed with the Securities and Exchange Commission on May 12, 2025 As filed with the Securities and Exchange Commission on May 12, 2025 Registration No. |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34951 XTANT MED |
|
| May 12, 2025 |
As filed with the Securities and Exchange Commission on May 12, 2025 As filed with the Securities and Exchange Commission on May 12, 2025 Registration No. |
|
| April 16, 2025 |
Exhibit 99.1 Xtant Medical Announces Secondary Private Sale of Existing Shares by OrbiMed and Preliminary First Quarter 2025 Revenue Growth of 18% to 19% Healthcare Focused Long-term Investors Support Strategic Vision Accelerating Shift to Higher-Margin Orthobiologics Supported by New Product Launches BELGRADE, Mont., April 16, 2025 — Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global me |
|
| April 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2025 XTANT MEDICAL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34951 20-5313323 (State or other jurisdiction of incorporation) (Commis |
|
| April 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2025 XTANT MEDICAL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34951 20-5313323 (State or other jurisdiction of incorporation) (Commis |
|
| April 11, 2025 |
Exhibit 10.3 amendment No. 2 to AMENDED AND RESTATED CREDIT, SECURITY AND GUARANTY AGREEMENT (REVOLVING LOAN) This AMENDMENT NO. 2 TO AMENDED AND RESTATED CREDIT, SECURITY AND GUARANTY AGREEMENT (REVOLVING LOAN) (this “Agreement”) is made as of April 9, 2025, by and among XTANT MEDICAL, INC., a Delaware corporation (“Xtant”), BACTERIN INTERNATIONAL, INC., a Nevada corporation, X-SPINE SYSTEMS, INC |
|
| April 11, 2025 |
Exhibit 10.2 amendment No. 2 to AMENDED AND RESTATED CREDIT, SECURITY AND GUARANTY AGREEMENT (TERM LOAN) This AMENDMENT NO. 2 TO AMENDED AND RESTATED CREDIT, SECURITY AND GUARANTY AGREEMENT (TERM LOAN) (this “Agreement”) is made as of April 9, 2025, by and among XTANT MEDICAL, INC., a Delaware corporation (“Xtant”), BACTERIN INTERNATIONAL, INC., a Nevada corporation, X-SPINE SYSTEMS, INC., an Ohio |
|
| April 11, 2025 |
Exhibit 10.1 XTANT MEDICAL HOLDINGS, INC. REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of April 10, 2025, by and between Xtant Medical Holdings, Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement i |
|
| March 6, 2025 |
Exhibit 99.1 Xtant Medical Reports Fourth Quarter and Full Year 2024 Financial Results Full Year 2024 Revenue Growth of 28% Expects 2025 Revenue of $126 Million to $130 Million Without Need for Additional Capital BELGRADE, Mont., March 6, 2025 — Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorder |
|
| March 6, 2025 |
Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries Entity Name State or Other Jurisdiction of Incorporation or Organization Bacterin International, Inc. Nevada Surgalign SPV, Inc. Delaware X-spine Systems, Inc. Ohio Xtant Medical, Inc. Delaware RTI Surgical Holdings Luxembourg SARL Luxembourg Surgalign UK Limited United Kingdom RTI Surgical – Singapore Pte. Ltd. Singapore Paradigm Spine GmbH Germany Fourth Dimension Spine |
|
| March 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34951 Xtant Medical |
|
| March 6, 2025 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2025 XTANT MEDICAL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34951 20-5313323 (State or other jurisdiction of incorporation) (Commiss |
|
| March 6, 2025 |
Xtant Medical Holdings, Inc. Insider Trading Policy Exhibit 19.1 XTANT MEDICAL HOLDINGS, INC. INSIDER TRADING POLICY Xtant Medical Holdings, Inc. has adopted the following insider trading policy (this “Policy”) in order to comply with United States federal and state securities laws governing: (a) transactions in the Company’s securities while in the possession of “material nonpublic information” concerning the Company, and (b) tipping or disclosing |
|
| November 12, 2024 |
Exhibit 99.1 Xtant Medical Reports Third Quarter 2024 Financial Results Third Quarter Revenue Growth of 12% Reaffirms Full Year 2024 Revenue Guidance of $116 Million to $120 Million Representing Growth of 27% to 31% BELGRADE, Mont., Nov. 12, 2024 — Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disor |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 XTANT MEDICAL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34951 20-5313323 (State or other jurisdiction of incorporation) (Com |
|
| November 12, 2024 |
Exhibit 10.3 SEPARATION AGREEMENT This Separation Agreement (“Agreement”) and the Release, which is attached and incorporated by reference as Exhibit A (“Release”), are made by and between Kevin D. Brandt (“Employee”), and Xtant Medical Holdings, Inc., its affiliates, related or predecessor corporations, subsidiaries, successors and assigns (“Employer”). Employer and Employee (collectively, “Parti |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34951 XTANT |
|
| September 11, 2024 |
7,812,500 Shares of Common Stock 424B3 1 form424b3.htm Filed Pursuant to Rule 424(b)(3) Registration Statement No.: 333-281910 FINAL PROSPECTUS 7,812,500 Shares of Common Stock This prospectus relates to the resale, from time to time, of up to an aggregate of 7,812,500 shares of common stock, par value $0.000001 per share, of Xtant Medical Holdings, Inc. by the selling stockholders named in this prospectus, including their respec |
|
| September 10, 2024 |
XTNT / Xtant Medical Holdings, Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO. 12 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 12)* Xtant Medical Holdings, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 98420P308 (CUSIP Number) OrbiMed Advisors LLC OrbiMed ROF II LLC 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone: (212) 739-6400 (Name, Address and T |
|
| September 10, 2024 |
EX-99.1 2 ss3849381ex9901.htm JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that Amendment No. 12 to the Statement on Schedule 13D, dated September 3, 2024, with respect to the common stock of Xtant Medical Holdings, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 19 |
|
| September 9, 2024 |
664 Cruiser Lane Belgrade, Montana 59714 (406) 388-0480 664 Cruiser Lane Belgrade, Montana 59714 (406) 388-0480 September 9, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, DC 20549 Attention: Alan Campbell Re: Xtant Medical Holdings, Inc. |
|
| September 4, 2024 |
As filed with the Securities and Exchange Commission on September 4, 2024 As filed with the Securities and Exchange Commission on September 4, 2024 Registration Statement No. |
|
| September 3, 2024 |
Exhibit 4.11 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of August 9, 2024, by and among Xtant Medical Holdings, Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to the Securiti |
|
| September 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 3, 2024 XTANT MEDICAL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34951 20-5313323 (State or other jurisdiction of incorporation) (Com |
|
| September 3, 2024 |
Exhibit 99.1 SURGALIGN HOLDINGS, INC. AND SUBSIDIARIES Condensed Consolidated Balance Sheets (Unaudited, in thousands, except share data) June 30, 2023 December 31, 2022 Assets Current Assets: Cash and cash equivalents $ 14,992 $ 16,295 Accounts receivable - less allowances of $9,890 at June 30, 2023 and $9,861 at December 31, 2022 10,058 16,057 Inventories - current 9,400 17,710 Prepaid and other |
|
| September 3, 2024 |
As filed with the U.S. Securities and Exchange Commission on September 3, 2024 As filed with the U.S. Securities and Exchange Commission on September 3, 2024 Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Xtant Medical holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 20-5313323 (State or other jurisdiction of incorporation or |
|
| September 3, 2024 |
Calculation of Filing Fee Tables Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Xtant Medical Holdings, Inc. |
|
| September 3, 2024 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Exhibit 99.2 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION The following unaudited pro forma condensed combined financial statements present the combination of the historical financial statements of Xtant Medical Holdings, Inc., a Delaware corporation (“Xtant” or the “Company”), and Surgalign Holdings, Inc. (“Surgalign Holdings”), a Delaware corporation, adjusted to give effect to t |
|
| August 8, 2024 |
EXHIBIT 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of August 9, 2024, by and among Xtant Medical Holdings, Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to the Securiti |
|
| August 8, 2024 |
Xtant Medical Announces $5.0 Million Private Placement Exhibit 99.1 Xtant Medical Announces $5.0 Million Private Placement BELGRADE, MT, August 8, 2024 – Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced it has entered into a securities purchase agreement with an existing institutional investor to sell shares of its common stock i |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34951 XTANT MEDI |
|
| August 8, 2024 |
Exhibit 10.2 AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT This Amendment No. 1 to Employment Agreement (“Amendment”) is effective as of August 8, 2024 (“Effective Date”), by and between Xtant Medical Holdings, Inc., a Delaware corporation (the “Company”), and Sean E. Browne, an individual (“Employee”). The Company and Employee are sometimes referred to as the “Parties” or “Party” in this Amendment. The |
|
| August 8, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of August 7, 2024, among Xtant Medical Holdings, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditi |
|
| August 8, 2024 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 XTANT MEDICAL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34951 20-5313323 (State or other jurisdiction of incorporation) (Commis |
|
| August 8, 2024 |
Xtant Medical Reports Second Quarter 2024 Revenue Growth of 48% Exhibit 99.1 Xtant Medical Reports Second Quarter 2024 Revenue Growth of 48% BELGRADE, Mont., August 8, 2024 — Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the second quarter ended June 30, 2024. Second Quarter 2024 Financial Highlights |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2024 XTANT MEDICAL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34951 20-5313323 (State or other jurisdiction of incorporation) (Commis |
|
| August 8, 2024 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION (THE “COMMISSION”) OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO A |
|
| July 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2024 XTANT MEDICAL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34951 20-5313323 (State or other jurisdiction of incorporation) (Commiss |
|
| June 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e |
|
| May 15, 2024 |
Exhibit 10.5 amendment No. 1 to AMENDED AND RESTATED CREDIT, SECURITY AND GUARANTY AGREEMENT (REVOLVING LOAN) This AMENDMENT NO. 1 TO AMENDED AND RESTATED CREDIT, SECURITY AND GUARANTY AGREEMENT (REVOLVING LOAN) (this “Agreement”) is made as of May 14, 2024, by and among XTANT MEDICAL, INC., a Delaware corporation (“Xtant”), BACTERIN INTERNATIONAL, INC., a Nevada corporation, X-SPINE SYSTEMS, INC. |
|
| May 15, 2024 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2024 XTANT MEDICAL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34951 20-5313323 (State or other jurisdiction of incorporation) (Commissi |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34951 XTANT MED |
|
| May 15, 2024 |
Exhibit 10.1 [Executive Officer – Time-Based Vesting/Deferred Settlement] NOTICE OF DEFERRED STOCK UNIT GRANT UNDER THE XTANT MEDICAL HOLDINGS, INC. 2023 equity INCENTIVE PLAN Xtant Medical Holdings, Inc., a Delaware corporation (the “Company”), pursuant to the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan (as may be amended from time to time, the “Plan”), hereby grants to the individual |
|
| May 15, 2024 |
Exhibit 99.1 Xtant Medical Reports First Quarter 2024 Revenue Growth of 55% and Raises Full Year 2024 Revenue Guidance Expects Revenue for Full Year 2024 of $116 Million to $120 Million BELGRADE, MT, May 15, 2024 (GLOBE NEWSWIRE) - Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today repor |
|
| May 15, 2024 |
exhibit 10.4 amendment No. 1 to AMENDED AND RESTATED CREDIT, SECURITY AND GUARANTY AGREEMENT (TERM LOAN) This AMENDMENT NO. 1 TO AMENDED AND RESTATED CREDIT, SECURITY AND GUARANTY AGREEMENT (TERM LOAN) (this “Agreement”) is made as of May 14, 2024, by and among XTANT MEDICAL, INC., a Delaware corporation (“Xtant”), BACTERIN INTERNATIONAL, INC., a Nevada corporation, X-SPINE SYSTEMS, INC., an Ohio |
|
| April 4, 2024 |
664 Cruiser Lane Belgrade, Montana 59714 (406) 388-0480 664 Cruiser Lane Belgrade, Montana 59714 (406) 388-0480 April 4, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, DC 20549 Attention: Jimmy McNamara Re: Xtant Medical Holdings, Inc. |
|
| April 1, 2024 |
Xtant Medical Holdings, Inc. Clawback Policy Exhibit 97.1 XTANT MEDICAL HOLDINGS, Inc. CLAWBACK POLICY This Xtant Medical Holdings, Inc. Clawback Policy (this “Policy”) was approved effective as of October 2, 2023 (the “Effective Date”) by the Compensation Committee (the “Committee”) of the Board of Directors (the “Board”) of Xtant Medical Holdings, Inc. (the “Company”). This Policy is adopted pursuant to and intended to comply with Section |
|
| April 1, 2024 |
Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries Entity Name State or Other Jurisdiction of Incorporation or Organization Bacterin International, Inc. Nevada Surgalign SPV, Inc. Delaware X-spine Systems, Inc. Ohio Xtant Medical, Inc. Delaware RTI Surgical Holdings Luxembourg SARL Luxembourg Surgalign UK Limited United Kingdom RTI Surgical – Singapore Pte. Ltd. Singapore Paradigm Spine GmbH Germany Fourth Dimension Spine |
|
| April 1, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Xtant Medical Holdings, Inc. |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34951 Xtant Medical |
|
| April 1, 2024 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2024 XTANT MEDICAL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34951 20-5313323 (State or other jurisdiction of incorporation) (Commiss |
|
| April 1, 2024 |
Exhibit 99.1 Xtant Medical Announces Record Full Year 2023 Revenue of $91.3 Million Establishes Full Year 2024 Revenue Guidance of $112 Million - $116 Million BELGRADE, MT, April 1, 2024 – Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the |
|
| April 1, 2024 |
Exhibit 10.14 INDEMNIFICATION AGREEMENT This Indemnification Agreement (“Agreement”) is made as of by and between Xtant Medical Holdings, Inc., a Delaware corporation (the “Company”), and , a resident of the State of (“Indemnitee”). This Agreement supplements any and all previous Agreements between the Company and Indemnitee covering the subject matter of this Agreement. Any conflict between this |
|
| April 1, 2024 |
As filed with the Securities and Exchange Commission on April 1, 2024 As filed with the Securities and Exchange Commission on April 1, 2024 Registration Statement No. |
|
| April 1, 2024 |
Exhibit 2.4 SECOND AMENDMENT TO ASSET PURCHASE AGREEMENT This Second Amendment to Asset Purchase Agreement (this “Amendment No. 2”) is made as of this 20th day of July 2023, by and between Xtant Medical Holdings, Inc., a Delaware corporation (the “Purchaser”), and Surgalign Holdings, Inc., a Delaware corporation (“Seller” and together with Purchaser, the “Parties”). WITNESSETH: WHEREAS, Purchaser |
|
| April 1, 2024 |
Exhibit 2.5 THIRD AMENDMENT TO ASSET PURCHASE AGREEMENT This Third Amendment to Asset Purchase Agreement (this “Amendment No. 3”) is made as of this 24th day of July 2023, by and between Xtant Medical Holdings, Inc., a Delaware corporation (the “Purchaser”), and Surgalign Holdings, Inc., a Delaware corporation (“Seller” and together with Purchaser, the “Parties”). WITNESSETH: WHEREAS, Purchaser an |
|
| April 1, 2024 |
Exhibit 10.13 [Employee – Performance Stock Units] NOTICE OF PERFORMANCE STOCK UNIT GRANT UNDER THE XTANT MEDICAL HOLDINGS, INC. 2023 equity INCENTIVE PLAN Xtant Medical Holdings, Inc., a Delaware corporation (the “Company”), pursuant to the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan (as may be amended from time to time, the “Plan”), hereby grants to the individual named below (the “P |
|
| April 1, 2024 |
Exhibit 4.1 XTANT MEDICAL HOLDINGS, INC. DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Xtant Medical Holdings, Inc., a Delaware corporation (Xtant, we, us and our), has only one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock, par value $0.000001 (common stock). The following d |
|
| March 7, 2024 |
Xtant Medical Increases Revolving Credit Facility to $17 Million with MidCap Financial Exhibit 99.1 Xtant Medical Increases Revolving Credit Facility to $17 Million with MidCap Financial BELGRADE, MT, March 7, 2024 – Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that the Company’s revolving credit agreement with MidCap Financial Trust (“MidCap”) was amended |
|
| March 7, 2024 |
Exhibit 10.1 Execution Version AMENDED AND RESTATED CREDIT, SECURITY AND GUARANTY AGREEMENT (term Loan) dated as of March 7, 2024 by and among XTANT MEDICAL, INC., BACTERIN INTERNATIONAL, INC., X-SPINE SYSTEMS, INC., SURGALIGN SPV, INC., and any additional borrower that hereafter becomes party hereto, each as Borrower, and collectively as Borrowers, XTANT MEDICAL HOLDINGS, INC., and any additional |
|
| March 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2024 XTANT MEDICAL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34951 20-5313323 (State or other jurisdiction of incorporation) (Commiss |
|
| March 7, 2024 |
Exhibit 10.2 Execution Version AMENDED AND RESTATED CREDIT, SECURITY AND GUARANTY AGREEMENT (REVOLVING Loan) dated as of March 7, 2024 by and among XTANT MEDICAL, INC., BACTERIN INTERNATIONAL, INC., X-SPINE SYSTEMS, INC., SURGALIGN SPV, INC., and any additional borrower that hereafter becomes party hereto, each as Borrower, and collectively as Borrowers, XTANT MEDICAL HOLDINGS, INC., and any addit |
|
| February 13, 2024 |
SC 13G/A 1 xtnt-sc13ga123123.htm AMENDMENT TO FORM SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Xtant Medical Holdings, Inc. (Name of Issuer) Common Stock, par value $0.000001 per share (Title of Class of Securities) 98420P308 (CUSIP Number) December 31, 2023 (Date of Event Which Requires |
|
| November 14, 2023 |
Exhibit 10.9 Execution Version Limited consent and amendment No. 4 to CREDIT, SECURITY AND GUARANTY AGREEMENT (REVOLVING LOAN) This LIMITED CONSENT AND AMENDMENT NO. 4 TO CREDIT, SECURITY AND GUARANTY AGREEMENT (REVOLVING LOAN) (this “Agreement”) is made as of August 10, 2023, by and among XTANT MEDICAL HOLDINGS, INC., a Delaware corporation (“Holdings”) as a Guarantor, each of Holdings’ direct an |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34951 XTANT |
|
| November 14, 2023 |
Exhibit 10.8 Execution Version Limited consent and amendment No. 4 to CREDIT, SECURITY AND GUARANTY AGREEMENT (TERM LOAN) This LIMITED CONSENT AND AMENDMENT NO. 4 TO CREDIT, SECURITY AND GUARANTY AGREEMENT (TERM LOAN) (this “Agreement”) is made as of August 10, 2023, by and among XTANT MEDICAL HOLDINGS, INC., a Delaware corporation (“Holdings”) as a Guarantor, each of Holdings’ direct and indirect |
|
| November 14, 2023 |
Exhibit 3.1 Delaware Page 1 The First State I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE RESTATED CERTIFICATE OF “XTANT MEDICAL HOLDINGS, INC.”, FILED IN THIS OFFICE ON THE FIFTEENTH DAY OF AUGUST, A.D. 2023, AT 10:14 O`CLOCK A.M. /s/ Jeffrey W. Bullock Jeffrey W. Bullock, Secretary of State 4202199 8100 Authen |
|
| November 9, 2023 |
Exhibit 99.1 Xtant Medical Announces Record Third Quarter Revenue of $25 Million Raises 2023 Annual Revenue Guidance to $88 Million - $91 Million BELGRADE, MT, November 9, 2023 – Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the third qua |
|
| November 9, 2023 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 XTANT MEDICAL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34951 20-5313323 (State or other jurisdiction of incorporation) (Comm |
|
| October 26, 2023 |
Exhibit 99.1 SURGALIGN HOLDINGS, INC. AND SUBSIDIARIES Condensed Consolidated Balance Sheets (Unaudited, in thousands, except share data) March 31, 2023 December 31, 2022 Assets Current Assets: Cash and cash equivalents $ 22,430 $ 16,295 Accounts receivable - less allowances of $9,890 at March 31, 2023 and $9,861 at December 31, 2022 12,575 16,057 Inventories - current 13,530 17,710 Prepaid and ot |
|
| October 26, 2023 |
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS AND FINANCIAL STATEMENT SCHEDULE Exhibit 99.2 INDEX TO CONSOLIDATED FINANCIAL STATEMENTS AND FINANCIAL STATEMENT SCHEDULE Page Consolidated Financial Statements of Surgalign Holdings, Inc. and Subsidiaries Report of Independent Registered Public Accounting Firm (PCAOB ID Number 248) F-2 – F-3 Consolidated Balance Sheets—December 31, 2022 and 2021 F-4 Consolidated Statements of Comprehensive Loss —Years Ended December 31, 2022 and |
|
| October 26, 2023 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Exhibit 99.3 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION The following unaudited pro forma condensed combined financial statements present the combination of the historical financial statements of Xtant Medical Holdings, Inc., a Delaware corporation (“Xtant” or the “Company”), and Surgalign Holdings, Inc. (“Surgalign Holdings”), a Delaware corporation, adjusted to give effect to t |
|
| October 26, 2023 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 XTANT MEDICAL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34951 20-5313323 (State or other jurisdiction of i |
|
| October 23, 2023 |
Regulation FD Disclosure, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 23, 2023 XTANT MEDICAL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34951 20-5313323 (State or other jurisdiction of incorporation) (Comm |
|
| October 23, 2023 |
Exhibit 99.1 Xtant Medical Announces Acquisition of nanOss Production Operations from RTI Surgical Expands Xtant’s Manufacturing Capabilities and Capacity to Drive Growth BELGRADE, MT, October 23, 2023 – Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it has acquired th |
|
| August 18, 2023 |
Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2023 XTANT MEDICAL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34951 20-5313323 (State or other jurisdiction of incorporation) (Commi |
|
| August 18, 2023 |
Exhibit 16.1 August 18, 2023 U.S. Securities and Exchange Commission Washington, D.C. 20549 Commissioners, We have read Item 4.01 included in the Form 8-K of Xtant Medical Holdings, Inc., which we understand will be filed with the Securities and Exchange Commission on or soon after August 18, 2023 in regard to its change in auditors. We agree with the statements made regarding our firm. We have no |
|
| August 10, 2023 |
Xtant Medical Completes Acquisition of Surgalign’s Hardware and Biologics Business Exhibit 99.1 Xtant Medical Completes Acquisition of Surgalign’s Hardware and Biologics Business BELGRADE, MT, August 10, 2023 – Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it completed the acquisition of certain assets and liabilities related to the domestic and int |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 XTANT MEDICAL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34951 20-5313323 (State or other jurisdiction of incorporation) (Commi |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 XTANT MEDICAL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34951 20-5313323 (State or other jurisdiction of incorporation) (Commis |
|
| August 3, 2023 |
XTNT / Xtant Medical Holdings Inc / ORBIMED ADVISORS LLC - AMENDMENT NO. 11 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 11)* Xtant Medical Holdings, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 98420P308 (CUSIP Number) OrbiMed Advisors LLC OrbiMed ROF II LLC 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone: (212) 739-6400 (Name, Address and T |
|
| August 3, 2023 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that Amendment No. 11 to the Statement on Schedule 13D, dated August 1, 2023, with respect to the common stock of Xtant Medical Holdings, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. Each of the undersigned agrees to be res |
|
| August 1, 2023 |
Exhibit 99.1 Xtant Medical Announces Second Quarter Revenue Growth of 32% Raises 2023 Annual Revenue Guidance to $75 Million - $77 Million BELGRADE, MT, August 1, 2023 – Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the second quarter end |
|
| August 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34951 XTANT MEDI |
|
| August 1, 2023 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2023 XTANT MEDICAL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34951 20-5313323 (State or other jurisdiction of incorporation) (Commis |
|
| July 28, 2023 |
As filed with the Securities and Exchange Commission on July 28, 2023 As filed with the Securities and Exchange Commission on July 28, 2023 Registration No. |
|
| July 28, 2023 |
Exhibit 10.2 [Employee – Time-Based Vesting] NOTICE OF OPTION GRANT UNDER THE XTANT MEDICAL HOLDINGS, INC. 2023 equity INCENTIVE PLAN Xtant Medical Holdings, Inc., a Delaware corporation (the “Company”), pursuant to the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan (as may be amended from time to time, the “Plan”), hereby grants to the individual named below (the “Participant”) a Non-Sta |
|
| July 28, 2023 |
As filed with the Securities and Exchange Commission on July 28, 2023 As filed with the Securities and Exchange Commission on July 28, 2023 Registration Nos. |
|
| July 28, 2023 |
Exhibit 3.3 CERTIFICATE OF AMENDMENT OF THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF XTANT MEDICAL HOLDINGS, INC. Xtant Medical Holdings, Inc., a corporation organized and existing under and by virtue of the laws of the State of Delaware (the “Corporation”), pursuant to the provisions of the General Corporation Law of the State of Delaware (the “DGCL”), DOES HEREBY CERTIFY that: FIRST: |
|
| July 28, 2023 |
As filed with the Securities and Exchange Commission on July 28, 2023 As filed with the Securities and Exchange Commission on July 28, 2023 Registration Nos. |
|
| July 28, 2023 |
As filed with the Securities and Exchange Commission on July 28, 2023 As filed with the Securities and Exchange Commission on July 28, 2023 Registration Nos. |
|
| July 28, 2023 |
Exhibit 10.1 XTANT MEDICAL HOLDINGS, INC. 2023 EQUITY INCENTIVE PLAN (Effective July 26, 2023) Table of Contents 1. Purpose of Plan. 1 2. Definitions. 1 3. Plan Administration. 6 4. Shares Available for Issuance. 8 5. Participation. 10 6. Options. 10 7. Stock Appreciation Rights. 12 8. Restricted Stock Awards, Restricted Stock Units and Deferred Stock Units. 13 9. Performance Awards. 14 10. Non-Em |
|
| July 28, 2023 |
Exhibit 10.5 NOTICE OF DEFERRED STOCK UNIT GRANT UNDER THE XTANT MEDICAL HOLDINGS, INC. 2023 equity INCENTIVE PLAN Xtant Medical Holdings, Inc., a Delaware corporation (the “Company”), pursuant to the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan (as may be amended from time to time, the “Plan”), hereby grants to the individual named below (the “Participant”) the number of Deferred Stock |
|
| July 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2023 XTANT MEDICAL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34951 20-5313323 (State or other jurisdiction of incorporation) (Commiss |
|
| July 28, 2023 |
Exhibit 10.3 [Employee – Time-Based Vesting] NOTICE OF RESTRICTED STOCK UNIT GRANT UNDER THE XTANT MEDICAL HOLDINGS, INC. 2023 equity INCENTIVE PLAN Xtant Medical Holdings, Inc., a Delaware corporation (the “Company”), pursuant to the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan (as may be amended from time to time, the “Plan”), hereby grants to the individual named below (the “Particip |
|
| July 28, 2023 |
Exhibit 99.1 Xtant Medical Wins Auction for Surgalign’s Hardware and Biologics Business Acquisition to Enhance Xtant’s Growing Spinal Fusion Devices Portfolio BELGRADE, MT, July 28, 2023 – Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it was the successful bidder for |
|
| July 28, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Xtant Medical Holdings, Inc. |
|
| July 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2023 XTANT MEDICAL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34951 20-5313323 (State or other jurisdiction of incorporation) (Commiss |
|
| July 28, 2023 |
Exhibit 10.4 NOTICE OF RESTRICTED STOCK UNIT GRANT UNDER THE XTANT MEDICAL HOLDINGS, INC. 2023 equity INCENTIVE PLAN Xtant Medical Holdings, Inc., a Delaware corporation (the “Company”), pursuant to the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan (as may be amended from time to time, the “Plan”), hereby grants to the individual named below (the “Participant”) the number of Restricted S |
|
| July 28, 2023 |
Exhibit 3.2 CERTIFICATE OF AMENDMENT OF THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF XTANT MEDICAL HOLDINGS, INC. Xtant Medical Holdings, Inc., a corporation organized and existing under and by virtue of the laws of the State of Delaware (the “Corporation”), pursuant to the provisions of the General Corporation Law of the State of Delaware (the “DGCL”), DOES HEREBY CERTIFY that: FIRST: |
|
| July 28, 2023 |
As filed with the Securities and Exchange Commission on July 28, 2023 As filed with the Securities and Exchange Commission on July 28, 2023 Registration Nos. |
|
| July 28, 2023 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT OF THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF XTANT MEDICAL HOLDINGS, INC. Xtant Medical Holdings, Inc., a corporation organized and existing under and by virtue of the laws of the State of Delaware (the “Corporation”), pursuant to the provisions of the General Corporation Law of the State of Delaware (the “DGCL”), DOES HEREBY CERTIFY that: FIRST: |
|
| July 14, 2023 |
20,000,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration Statement No.: 333-273169 FINAL PROSPECTUS 20,000,000 Shares of Common Stock This prospectus relates to the resale, from time to time, of up to an aggregate of 20,000,000 shares of common stock, par value $0.000001 per share, of Xtant Medical Holdings, Inc. by the selling stockholders named in this prospectus, including their respective donees, pledgee |
|
| July 11, 2023 |
664 Cruiser Lane Belgrade, Montana 59714 (406) 388-0480 664 Cruiser Lane Belgrade, Montana 59714 (406) 388-0480 July 11, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, DC 20549 Attention: Tim Buchmiller Re: Xtant Medical Holdings, Inc. |
|
| July 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2023 XTANT MEDICAL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34951 20-5313323 (State or other jurisdiction of incorporation) (Commiss |
|
| July 11, 2023 |
Exhibit 2.1 FIRST AMENDMENT TO ASSET PURCHASE AGREEMENT This First Amendment to Asset Purchase Agreement (this “Amendment”) is made as of this 10th day of July 2023, by and between Xtant Medical Holdings, Inc., a Delaware corporation (the “Purchaser”), and Surgalign Holdings, Inc., a Delaware corporation (“Seller” and together with Purchaser, the “Parties”). WITNESSETH: WHEREAS, Purchaser and Sell |
|
| July 11, 2023 |
As filed with the U.S. Securities and Exchange Commission on July 11, 2023 As filed with the U.S. Securities and Exchange Commission on July 11, 2023 Registration Statement No. 333-273169 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 PRE-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Xtant Medical holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 20-5313323 (State or oth |
|
| July 7, 2023 |
As filed with the U.S. Securities and Exchange Commission on July 7, 2023 As filed with the U.S. Securities and Exchange Commission on July 7, 2023 Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Xtant Medical holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 20-5313323 (State or other jurisdiction of incorporation or orga |
|
| July 7, 2023 |
Exhibit 4.9 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of July 6, 2023, by and among Xtant Medical Holdings, Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to the Securities |
|
| July 7, 2023 |
Calculation of Filing Fee Tables Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Xtant Medical Holdings, Inc. |
|
| July 3, 2023 |
Xtant Medical Announces $15 Million Private Placement Exhibit 99.2 Xtant Medical Announces $15 Million Private Placement BELGRADE, MT, July 3, 2023 – Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced it has entered into a securities purchase agreement with accredited investors to sell shares of its common stock in a private place |
|
| July 3, 2023 |
Investor Presentation of Xtant Medical Holdings, Inc. (furnished herewith) Exhibit 99.1 |
|
| July 3, 2023 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of July 3, 2023, among Xtant Medical Holdings, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and condition |
|
| July 3, 2023 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of , 2023, by and among Xtant Medical Holdings, Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to the Securities Purch |
|
| July 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 3, 2023 XTANT MEDICAL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34951 20-5313323 (State or other jurisdiction of incorporation) (Commissi |
|
| June 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2023 XTANT MEDICAL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34951 20-5313323 (State or other jurisdiction of incorporation) (Commiss |
|
| June 20, 2023 |
Exhibit 2.1 Execution Version ASSET PURCHASE AGREEMENT dated as of June 18, 2023 by and between Surgalign Holdings, Inc., and Xtant Medical Holdings, Inc. ASSET PURCHASE AGREEMENT This ASSET PURCHASE AGREEMENT (“Agreement”) is entered into as of June 18, 2023 by and between Xtant Medical Holdings, Inc., a Delaware corporation (the “Purchaser”), and Surgalign Holdings, Inc., a Delaware corporation |
|
| June 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e |
|
| May 19, 2023 |
Exhibit 3.1 THIRD AMENDED AND RESTATED BYLAWS OF XTANT MEDICAL HOLDINGS, INC. (Effective as of June 1, 2023) Article I Meetings of Stockholders Section 1.1. Annual Meetings. If required by applicable law, an annual meeting of stockholders of Xtant Medical Holdings, Inc. (the “corporation”) shall be held for the election of directors either at such date, time and place, if any, either within or wit |
|
| May 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e |
|
| May 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2023 XTANT MEDICAL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34951 20-5313323 (State or other jurisdiction of incorporation) (Commissi |
|
| May 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2023 XTANT MEDICAL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34951 20-5313323 (State or other jurisdiction of incorporation) (Commissi |
|
| May 18, 2023 |
Xtant Medical Appoints Lori Mitchell-Keller to Board of Directors Exhibit 99.1 Xtant Medical Appoints Lori Mitchell-Keller to Board of Directors BELGRADE, MT, May 18, 2023 – Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the appointment of Lori Mitchell-Keller to the Company’s Board of Directors effective May 16, 2023. Ms. Mitchell-Keller |
|
| May 16, 2023 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2023 XTANT MEDICAL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34951 20-5313323 (State or other jurisdiction of incorporation) (C |
|
| May 16, 2023 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Exhibit 99.2 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION On February 28, 2023, Xtant Medical Holdings, Inc., a Delaware corporation (“Xtant” or the “Company”), entered into an Equity Purchase Agreement (the “Equity Purchase Agreement”) with Surgalign SPV, Inc. (“Surgalign SPV”), a Delaware corporation and wholly owned subsidiary of Surgalign Spine Technologies, Inc., a Delaware co |
|
| May 16, 2023 |
SURGALIGN SPV, INC. ABBREVIATED FINANCIAL STATEMENTS TABLE OF CONTENTS Exhibit 99.1 SURGALIGN SPV, INC. ABBREVIATED FINANCIAL STATEMENTS TABLE OF CONTENTS Report of Independent Auditors 2 Statements of Assets Acquired as of December 31, 2021 and September 30, 2022 (Unaudited) 4 Statements of Revenues and Direct Expenses for the year ended December 31, 2021, and for the nine months ended September 30, 2022 (Unaudited) 5 Notes to Abbreviated Financial Statements 6 INDE |
|
| May 5, 2023 |
XTNT / Xtant Medical Holdings Inc / ORBIMED ADVISORS LLC - AMENDMENT NO. 10 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 10)* Xtant Medical Holdings, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 98420P308 (CUSIP Number) OrbiMed Advisors LLC OrbiMed ROF II LLC 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone: (212) 739-6400 (Name, Address and T |
|
| May 5, 2023 |
EX-99.1 2 ss2045947ex9901.htm JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that Amendment No. 10 to the Statement on Schedule 13D, dated May 1, 2023, with respect to the common stock of Xtant Medical Holdings, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as |
|
| May 4, 2023 |
Exhibit 10.1 INDEMNIFICATION AGREEMENT This Indemnification Agreement (“Agreement”) is made as of by and between Xtant Medical Holdings, Inc., a Delaware corporation (the “Company”), and , a resident of the State of (“Indemnitee”). This Agreement supplements any and all previous Agreements between the Company and Indemnitee covering the subject matter of this Agreement. Any conflict between this a |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 XTANT MEDICAL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34951 20-5313323 (State or other jurisdiction of incorporation) (Commissio |
|
| May 4, 2023 |
Exhibit 10.4 aMENDMENT NO. 1 TO INVESTOR rIGHTS AGREEMENT This Amendment NO. 1 TO INVESTOR rIGHTS AGREEMENT, dated as of May 2, 2023 (this “Amendment”), is made by and among Xtant Medical Holdings, Inc. (the “Company”), OrbiMed Royalty Opportunities II, LP (“OrbiMed”), ROS Acquisition Offshore LP (“ROS” and, together with OrbiMed, the “Investors”). WHEREAS, the parties hereto are parties to that c |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34951 XTANT MED |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2023 XTANT MEDICAL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34951 20-5313323 (State or other jurisdiction of incorporation) (Commissio |
|
| May 4, 2023 |
Exhibit 99.1 Xtant Medical Announces First Quarter 2023 Revenue Growth of 38% and Full Year 2023 Revenue Guidance Initiates Annual Revenue Guidance of $73 Million - $75 Million in Full Year 2023 BELGRADE, MT, May 4, 2023 – Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported finan |
|
| March 7, 2023 |
Exhibit 10.34 TRIPLE NET COMMERCIAL LEASE This TRIPLE NET COMMERCIAL LEASE (“Lease”), is made and entered into this 23 day of October, 2015 by and between Shep Does Stuff LLC, a Montana limited liability company of Montana herein referred to as “Landlord”, and BACTERIN INTERNATIONAL, INC., a Nevada corporation of 600 Cruiser Lane, Belgrade, Montana 59714, herein referred to as “Tenant”. In conside |
|
| March 7, 2023 |
Exhibit 10.32 ADDENDUM TO COMMERCIAL LEASE BETWEEN CRUISER LANE LLC AND BACTERIN INTERNATIONAL HOLDINGS, INC. (a/k/a, XTANT MEDICAL, INC.) DATED: July 29, 2022 The parties to this Addendum to Commercial lease are Cruiser Lane, LLC (hereinafter known as Landlord) and Xtant Medical, Inc., formerly known as Bacterin International Holdings, Inc. (referred to hereinafter as Tenant). This document serve |
|
| March 7, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2023 XTANT MEDICAL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34951 20-5313323 (State or other jurisdiction of incorporation) (Commiss |
|
| March 7, 2023 |
Exhibit 10.33 LEASE AGREEMENT THIS LEASE, made and entered into this 7th day of August, 2013, by and between McCLELLAN FARM, a Montana Corporation of Joplin, MT, or assigns, hereinafter designated “Lessor,” and BACTERIN INTERNATIONAL, INC., a Nevada corporation with an address at 600 Cruiser Lane, Belgrade, MT 59714, hereinafter designated “Lessee.” WITNESSETH Lessor does lease to Lessee approxima |
|
| March 7, 2023 |
Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries Entity Name State of Incorporation Bacterin International, Inc. Nevada Surgalign SPV, Inc. Delaware X-spine Systems, Inc. Ohio Xtant Medical, Inc. Delaware |
|
| March 7, 2023 |
Exhibit 10.31 ADDENDUM TO COMMERCIAL LEASE BETWEEN CRUISER LANE LLC AND BACTERIN INTERNATIONAL HOLDINGS, INC. (aka, XTANT MEDICAL, INC.) DATED: December 3, 2018 The parties to this Addendum to Commercial Lease are Cruiser Lane, LLC hereinafter known as Landlord and Xtant Medical, Inc. , formerly known as Bacterin International Holdings, Inc., now referred to hereinafter as Tenant. 1. Term: A term |
|
| March 7, 2023 |
Exhibit 10.30 COMMERCIAL LEASE 1 THIS IS INTENDED TO BE A LEGALLY BINDING CONTRACT, INCLUDING THE 2 SPECIFIC AND GENERAL TERMS DESCRIBED BELOW. IF NOT UNDERSTOOD, 3 LANDLORD(S) AND TENANT(S) ARE ADVISED TO SEEK THE ADVICE OF 4 COMPETENT LEGAL COUNSEL 6 SPECIFIC TERMS 8 PARTIES: The parties to this Commercial Lease are Cruiser Lane, LLC 9 hereinafter known as “Landlord” and 10 Bacterin Internationa |
|
| March 7, 2023 |
Xtant Medical Announces Fourth Quarter and Full Year 2022 Financial Results EX-99.1 2 ex99-1.htm Exhibit 99.1 Xtant Medical Announces Fourth Quarter and Full Year 2022 Financial Results BELGRADE, MT, March 7, 2023 – Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the fourth quarter and year ended December 31, 2022. |
|
| March 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34951 Xtant Medical |
|
| March 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2023 XTANT MEDICAL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34951 20-5313323 (State or other jurisdiction of incorporation) (Com |
|
| March 1, 2023 |
Exhibit 10.3 Execution Version amendment No. 3 to CREDIT, SECURITY AND GUARANTY AGREEMENT (REVOLVING LOAN) This AMENDMENT NO. 3 TO CREDIT, SECURITY AND GUARANTY AGREEMENT (REVOLVING LOAN) (this “Agreement”) is made as of February 28, 2023, by and among XTANT MEDICAL HOLDINGS, INC., a Delaware corporation (“Holdings”) as a Guarantor, each of Holdings’ direct and indirect Subsidiaries set forth on t |
|
| March 1, 2023 |
EX-10.1 3 ex10-1.htm Exhibit 10.1 TRANSITION SERVICES AGREEMENT AMONG SURGALIGN SPV, INC., SURGALIGN SPINE TECHNOLOGIES, INC., AND XTANT MEDICAL HOLDINGS, INC. DATED FEBRUARY 28, 2023 TABLE OF CONTENTS 1. Definitions 4 2. Services 7 2.1 Transition Services 7 2.2 Transition Services Period 7 2.3 Additional Services 7 2.4 Use of Transition Services 8 2.5 Standard of Transition Services 8 2.6 Shortfa |
|
| March 1, 2023 |
Exhibit 10.2 Execution Version amendment No. 3 to CREDIT, SECURITY AND GUARANTY AGREEMENT (TERM LOAN) This AMENDMENT NO. 3 TO CREDIT, SECURITY AND GUARANTY AGREEMENT (TERM LOAN) (this “Agreement”) is made as of February 28, 2023, by and among XTANT MEDICAL HOLDINGS, INC., a Delaware corporation (“Holdings”) as a Guarantor, each of Holdings’ direct and indirect Subsidiaries set forth on the signatu |
|
| March 1, 2023 |
Exhibit 99.1 Xtant Medical Acquires Coflex® Product Line from Surgalign for $17 Million Expands Xtant’s Product Offering with the Leading PMA-Approved Intralaminar Stabilization Device Strengthens Surgalign’s Balance Sheet as it Embarks on its Digital Health Strategy BELGRADE, MT and DEERFIELD, ILL., March 1, 2023 – Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology co |
|
| March 1, 2023 |
Exhibit 2.1 Execution Version EQUITY PURCHASE AGREEMENT This EQUITY PURCHASE AGREEMENT (this “Agreement”) is entered into as of February 28, 2023, by and among Xtant Medical Holdings, Inc., a Delaware corporation (“Buyer”), Surgalign SPV, Inc. (the “Company”), a Delaware corporation and wholly owned subsidiary of Surgalign Spine Technologies, Inc., a Delaware corporation (“Seller”), Seller and Sur |
|
| February 14, 2023 |
Joint Acquisition Statement Pursuant to Section 240.13d-1(k) EX-1 2 ex-1.htm JOINT ACQUISITION STATEMENT Altium Capital Management, LP SC 13G/A Page 9 of 9 EXHIBIT 1 JOINT ACQUISITION STATEMENT PURSUANT TO SECTION 240.13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of |
|
| February 14, 2023 |
SC 13G/A 1 xtnt-sc13ga123122.htm AMENDMENT TO SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Xtant Medical Holdings, Inc. (Name of Issuer) Common Stock, par value $0.000001 per share (Title of Class of Securities) 98420P308 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filin |
|
| February 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2023 XTANT MEDICAL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34951 20-5313323 (State or other jurisdiction of incorporation) (Comm |
|
| January 9, 2023 |
Xtant Medical Appoints Mark Schallenberger as Chief Operations Officer Exhibit 99.1 Xtant Medical Appoints Mark Schallenberger as Chief Operations Officer BELGRADE, MT, January 9, 2023 – Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the appointment of Mark Schallenberger as Chief Operations Officer, effective January 16, 2023. “We are thrille |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 XTANT MEDICAL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34951 20-5313323 (State or other jurisdiction of incorporation) (Commi |
|
| January 9, 2023 |
Exhibit 10.4 CONFIDENTIAL December 14, 2022 Mark Schallenberger 3425 North 38th Place Phoenix, AZ 85018 Subject: Offer of Employment Dear Mark: I am pleased to offer you the position of Chief Operations Officer (COO) of Xtant Medical Holdings, Inc. (“Xtant”). The most critical initial terms of your employment are set forth on the attached Term Sheet. This Offer is contingent upon your commencement |
|
| January 9, 2023 |
EX-10.1 2 ex10-1.htm Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is effective as of January 16, 2023 (“Effective Date”), by and between Xtant Medical Holdings, Inc., a Delaware corporation (the “Company”), and Mark A. Schallenberger, an individual (“Employee”). The Company and Employee are sometimes referred to as the “Parties” or “Party” in this Agreement, and the Co |
|
| November 3, 2022 |
Xtant Medical Announces Third Quarter 2022 Financial Results Exhibit 99.1 Xtant Medical Announces Third Quarter 2022 Financial Results BELGRADE, MT, November 3, 2022 ? Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the third quarter ended September 30, 2022. ?I am pleased that third quarter revenues |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34951 XTANT |
|
| November 3, 2022 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2022 XTANT MEDICAL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34951 20-5313323 (State or other jurisdiction of incorporation) (Comm |
|
| November 3, 2022 |
EX-10.5 3 ex10-5.htm Exhibit 10.5 amendment No. 2 to CREDIT, SECURITY AND GUARANTY AGREEMENT (REVOLVING LOAN) This AMENDMENT NO. 2 TO CREDIT, SECURITY AND GUARANTY AGREEMENT (REVOLVING LOAN) (this “Agreement”) is made as of October 27, 2022, by and among XTANT MEDICAL HOLDINGS, INC., a Delaware corporation (“Holdings”) as a Guarantor, each of Holdings’ direct and indirect Subsidiaries set forth on |
|
| November 3, 2022 |
Exhibit 10.4 amendment No. 2 to CREDIT, SECURITY AND GUARANTY AGREEMENT (TERM LOAN) This AMENDMENT NO. 2 TO CREDIT, SECURITY AND GUARANTY AGREEMENT (TERM LOAN) (this ?Agreement?) is made as of October 27, 2022, by and among XTANT MEDICAL HOLDINGS, INC., a Delaware corporation (?Holdings?) as a Guarantor, each of Holdings? direct and indirect Subsidiaries set forth on the signature pages hereto as |
|
| October 28, 2022 |
EX-10.1 2 ex10-1.htm XTANT MEDICAL HOLDINGS, INC. SECOND AMENDED AND RESTATED 2018 EQUITY INCENTIVE PLAN (As amended on October 26, 2022) Table of Contents 1. Purpose of Plan. 1 2. Definitions. 1 3. Plan Administration. 6 4. Shares Available for Issuance. 8 5. Participation. 10 6. Options. 10 7. Stock Appreciation Rights. 12 8. Restricted Stock Awards, Restricted Stock Units and Deferred Stock Uni |
|
| October 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2022 XTANT MEDICAL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34951 20-5313323 (State or other jurisdiction of incorporation) (Comm |
|
| October 28, 2022 |
Filing Fee Table (filed herewith) Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Xtant Medical Holdings, Inc. |
|
| October 28, 2022 |
As filed with the Securities and Exchange Commission on October 28, 2022 S-8 1 forms-8.htm As filed with the Securities and Exchange Commission on October 28, 2022 Registration No. 333- United States SECURITIES AND EXCHANGE cOMMISSION Washington, D.C. 20549 fOrm S-8 registration statement under the securities act of 1933 Xtant Medical holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 20-5313323 (State or other jurisdiction of incorporation |
|
| October 20, 2022 |
25,381,787 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration Statement No.: 333-267817 FINAL PROSPECTUS 25,381,787 Shares of Common Stock This prospectus relates to the resale, from time to time, of up to an aggregate of 25,381,787 shares of common stock, par value $0.000001 per share, of Xtant Medical Holdings, Inc. by the selling stockholders named in this prospectus, including their respective donees, pledgee |
|
| October 18, 2022 |
664 Cruiser Lane Belgrade, Montana 59714 (406) 388-0480 664 Cruiser Lane Belgrade, Montana 59714 (406) 388-0480 October 18, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, DC 20549 Attention: Christine Westbrook Re: Xtant Medical Holdings, Inc. |
|
| October 11, 2022 |
Calculation of Filing Fee Tables Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Xtant Medical Holdings, Inc. |
|
| October 11, 2022 |
As filed with the U.S. Securities and Exchange Commission on October 11, 2022 As filed with the U.S. Securities and Exchange Commission on October 11, 2022 Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Xtant Medical holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 20-5313323 (State or other jurisdiction of incorporation or |
|
| October 11, 2022 |
Regulation FD Disclosure, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 7, 2022 XTANT MEDICAL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34951 20-5313323 (State or other jurisdiction of incorporation) (Commi |
|
| October 11, 2022 |
Xtant Medical Announces Closing of Second Tranche of $9.75 Million Private Investment Exhibit 99.1 Xtant Medical Announces Closing of Second Tranche of $9.75 Million Private Investment BELGRADE, MT, October 11, 2022 ? Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the closing of the second and final tranche of its previously announced private placement with |
|
| September 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ?) Filed by the Registrant ? Filed by a Party other than the Registrant ?? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted |
|
| September 9, 2022 |
DEF 14C 1 formdef14c.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☐ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☒ Definitive Information Statemen |
|
| September 6, 2022 |
XTNT / Xtant Medical Holdings Inc / Vizirgianakis Stavros G. - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Xtant Medical Holdings, Inc. (Name of Issuer) Common Stock, par value $0.000001 per share (Title of Class of Securities) 98420P308 (CUSIP Number) Mr. Stavros G. Vizirgianakis 664 Cruiser Lane Belgrade, Montana 59714 Telephone: 0027823791881 (Name, Address and Telephone Num |
|
| August 31, 2022 |
Xtant Medical Announces Closing of First Tranche of $9.75 Million Private Investment Exhibit 99.1 Xtant Medical Announces Closing of First Tranche of $9.75 Million Private Investment BELGRADE, MT, August 31, 2022 ? Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the closing of the first tranche of its previously announced private placement with a select grou |
|
| August 31, 2022 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this ?Agreement?) is made and entered into as of August 25, 2022, by and among Xtant Medical Holdings, Inc., a Delaware corporation (the ?Company?), and each of the several purchasers signatory hereto (each such purchaser, a ?Purchaser? and, collectively, the ?Purchasers?). This Agreement is made pursuant to the Securit |
|
| August 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 25, 2022 XTANT MEDICAL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34951 20-5313323 (State or other jurisdiction of incorporation) (Commi |
|
| August 31, 2022 |
Exhibit 10.3 XTANT MEDICAL HOLDINGS, INC. 664 Cruiser Lane Belgrade, Montana 59714 August 25, 2022 Via Email Mr. Stavros G. Vizirgianakis 273 Hillcrest Ln Oyster Bay, New York 11771 Dear Stavros: In connection with that certain Securities Purchase Agreement dated as of August 23, 2022 among Xtant Medical Holdings, Inc. (the ?Company) and the purchasers party thereto (the ?Purchase Agreement?), inc |
|
| August 30, 2022 |
XTNT / Xtant Medical Holdings Inc / ORBIMED ADVISORS LLC - AMENDMENT NO. 9 Activist Investment SC 13D/A 1 ss1288981sc13da.htm AMENDMENT NO. 9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 9)* Xtant Medical Holdings, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 98420P308 (CUSIP Number) OrbiMed Advisors LLC OrbiMed ROF II LLC 601 Lexington Avenue, 54th Floor New York, NY 10022 |
|
| August 30, 2022 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13D, dated August 26, 2022, with respect to the ordinary shares of Xtant Medical Holdings, Inc. |
|
| August 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ? Preliminary Information Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ? Definitive Information Statement XTANT MEDICAL HOLDINGS, |
|
| August 24, 2022 |
Exhibit 10.3 XTANT MEDICAL HOLDINGS, INC. 664 Cruiser Lane Belgrade, Montana 59714 August , 2022 Via Email Mr. Stavros G. Vizirgianakis 273 Hillcrest Ln Oyster Bay, New York 11771 Dear Stavros: In connection with that certain Securities Purchase Agreement dated as of August 23, 2022 among Xtant Medical Holdings, Inc. (the ?Company) and the purchasers party thereto (the ?Purchase Agreement?), inclu |
|
| August 24, 2022 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this ?Agreement?) is made and entered into as of August [], 2022, by and among Xtant Medical Holdings, Inc., a Delaware corporation (the ?Company?), and each of the several purchasers signatory hereto (each such purchaser, a ?Purchaser? and, collectively, the ?Purchasers?). This Agreement is made pursuant to the Securit |
|
| August 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 23, 2022 XTANT MEDICAL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34951 20-5313323 (State or other jurisdiction of incorporation) (Commi |
|
| August 24, 2022 |
Exhibit 10.1 Execution Version SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of August 23, 2022, among Xtant Medical Holdings, Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purchasers?). WHEREAS, subject to th |
|
| August 24, 2022 |
Exhibit 99.1 Xtant Medical Announces $9.75 Million Private Investment Upon completion of first closing, Stavros Vizirgianakis to become Non-Executive Chairman BELGRADE, MT, August 24, 2022 ? Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced it has entered into a securities pur |
|
| August 24, 2022 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| August 4, 2022 |
Xtant Medical Announces Second Quarter 2022 Financial Results Exhibit 99.1 Xtant Medical Announces Second Quarter 2022 Financial Results BELGRADE, MT, August 4, 2022 ? Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the second quarter ended June 30, 2022. ?We are pleased to have achieved our highest r |
|
| August 4, 2022 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 XTANT MEDICAL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34951 20-5313323 (State or other jurisdiction of incorporation) (Commis |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34951 XTANT MEDI |
|
| May 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34951 XTANT MED |
|
| May 5, 2022 |
Xtant Medical Announces First Quarter 2022 Financial Results Exhibit 99.1 Xtant Medical Announces First Quarter 2022 Financial Results BELGRADE, MT, May 5, 2022 ? Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the first quarter ended March 31, 2022. ?By building momentum in our business, underscored |
|
| May 5, 2022 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2022 XTANT MEDICAL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34951 20-5313323 (State or other jurisdiction of incorporation) (Commissio |
|
| May 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2022 XTANT MEDICAL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34951 20-5313323 (State or other jurisdiction of incorporation) (Commis |
|
| May 2, 2022 |
Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (?Agreement?) is effective as of June 1, 2022 (?Effective Date?), by and between Xtant Medical Holdings, Inc., a Delaware corporation (the ?Company?), and Scott C. Neils, an individual (?Employee?). The Company and Employee are sometimes referred to as the ?Parties? or ?Party? in this Agreement, and the Company may designate a subsidiary |
|
| March 8, 2022 |
Exhibit 10.10 RESIGNATION AGREEMENT AND RELEASE This Resignation Agreement (?Agreement?) and the Release, which is attached and incorporated by reference as Exhibit A (?Release?), are made by and between Greg Jensen (?Employee?), and Xtant Medical Holdings, Inc., its affiliates, related or predecessor corporations, subsidiaries, successors and assigns (?Employer?). Employer and Employee (collectiv |
|
| March 8, 2022 |
Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 Exhibit 4.1 XTANT MEDICAL HOLDINGS, INC. DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Xtant Medical Holdings, Inc., a Delaware corporation (Xtant, we, us and our), has only one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (Exchange Act): our common stock, par value $0.000001 (common stock). |
|
| March 8, 2022 |
Exhibit 10.19 amendment No. 1 to CREDIT, SECURITY AND GUARANTY AGREEMENT (TERM LOAN) This AMENDMENT NO. 1 TO CREDIT, SECURITY AND GUARANTY AGREEMENT (TERM LOAN) (this ?Agreement?) is made as of March 7, 2022, by and among XTANT MEDICAL HOLDINGS, INC., a Delaware corporation (?Holdings?) as a Guarantor, each of Holdings? direct and indirect Subsidiaries set forth on the signature pages hereto as a |
|
| March 8, 2022 |
United States Securities and Exchange Commission Washington, D.C. 20549 FORM 8-A/A (Amendment No. 1) FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 XTANT MEDICAL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 20-5313323 (State or other jurisdiction of incorporation or organization) (I.R.S. Em |
|
| March 8, 2022 |
Xtant Medical Announces Fourth Quarter and Full Year 2021 Financial Results Exhibit 99.1 Xtant Medical Announces Fourth Quarter and Full Year 2021 Financial Results BELGRADE, MT, March 8, 2022 ? Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the fourth quarter and year ended December 31, 2021. ?Xtant accomplished |
|
| March 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34951 Xtant Medical |
|
| March 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2022 XTANT MEDICAL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34951 20-5313323 (State or other jurisdiction of incorporation) (Commiss |
|
| March 8, 2022 |
Exhibit 4.2 |
|
| March 8, 2022 |
Exhibit 10.20 amendment No. 1 to CREDIT, SECURITY AND GUARANTY AGREEMENT (REVOLVING LOAN) This AMENDMENT NO. 1 TO CREDIT, SECURITY AND GUARANTY AGREEMENT (REVOLVING LOAN) (this ?Agreement?) is made as of March 7, 2022, by and among XTANT MEDICAL HOLDINGS, INC., a Delaware corporation (?Holdings?) as a Guarantor, each of Holdings? direct and indirect Subsidiaries set forth on the signature pages he |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Xtant Medical Holdings, Inc. (Name of Issuer) Common Stock, par value $0.000001 per share (Title of Class of Securities) 98420P308 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to des |
|
| February 14, 2022 |
JOINT ACQUISITION STATEMENT PURSUANT TO SECTION 240.13d-1(k) EX-1 2 ex-1.htm JOINT ACQUISITION STATEMENT Xtant Medical Holdings, Inc. SC 13G EXHIBIT 1 JOINT ACQUISITION STATEMENT PURSUANT TO SECTION 240.13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned |
|
| January 3, 2022 |
Xtant Medical Appoints Scott Neils Interim Chief Financial Officer Exhibit 99.1 Xtant Medical Appoints Scott Neils Interim Chief Financial Officer BELGRADE, MT, January 3, 2022 ? Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the appointment of Scott Neils as Interim Chief Financial Officer succeeding Greg Jensen, the Company?s current Vic |
|
| January 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2022 XTANT MEDICAL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34951 20-5313323 (State or other jurisdiction of incorporation) (Commi |
|
| January 3, 2022 |
Exhibit 10.1 December 28, 2021 Scott Neils [Address] Dear Mr. Neils: I am pleased to offer you the position of Interim Chief Financial Officer with Xtant Medical Holdings, Inc. The major terms of your employment offer are set forth on the attached TERM SHEET. Our proposed start date for the role is January 03, 2022, however let us know if this does not work for you. This is a full-time, exempt pos |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34951 XTANT |
|
| November 12, 2021 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2021 XTANT MEDICAL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34951 20-5313323 (State or other jurisdiction of incorporation) (Com |
|
| November 12, 2021 |
Xtant Medical Announces Third Quarter 2021 Financial Results EX-99.1 2 ex99-1.htm Exhibit 99.1 Xtant Medical Announces Third Quarter 2021 Financial Results BELGRADE, MT, November 12, 2021 – Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the third quarter ended September 30, 2021. Third Quarter 2021 |
|
| August 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34951 XTANT MEDI |
|
| August 5, 2021 |
Xtant Medical Announces Second Quarter 2021 Financial Results EX-99.1 2 ex99-1.htm Exhibit 99.1 Xtant Medical Announces Second Quarter 2021 Financial Results BELGRADE, MT, August 5, 2021 – Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the second quarter ended June 30, 2021. Second Quarter 2021 Finan |
|
| August 5, 2021 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2021 XTANT MEDICAL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34951 20-5313323 (State or other jurisdiction of incorporation) (Commis |
|
| July 28, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2021 XTANT MEDICAL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34951 20-5313323 (State or other jurisdiction of incorporation) (Commiss |
|
| June 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2) [X] Definitive Pr |
|
| May 20, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2021 XTANT MEDICAL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34951 20-5313323 (State or other jurisdiction (Commission (IRS Employer o |
|
| May 20, 2021 |
Investor Presentation (furnished herewith) EX-99.1 2 ex99-1.htm Exhibit 99.1 |
|
| May 14, 2021 |
664 Cruiser Lane Belgrade, Montana 59714 (406) 388-0480 664 Cruiser Lane Belgrade, Montana 59714 (406) 388-0480 May 14, 2021 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, DC 20549 Attention: Irene Paik Re: Xtant Medical Holdings, Inc. |
|
| May 11, 2021 |
Xtant Medical Announces First Quarter 2021 Financial Results EX-99.1 2 ex99-1.htm Exhibit 99.1 Xtant Medical Announces First Quarter 2021 Financial Results BELGRADE, MT, May 11, 2021 – Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the first quarter ended March 31, 2021. First Quarter 2021 Financial |
|
| May 11, 2021 |
As filed with the U.S. Securities and Exchange Commission on May 11, 2021 Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Xtant Medical holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 20-5313323 (State or other jurisdiction of incorporation or orga |
|
| May 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34951 XTANT |
